Padeliporfin Potassium
A potassium salt of padeliporfin (WST11), a photosensitizer used in vascular-targeted photodynamic therapy for localized low-risk prostate cancer. When activated by near-infrared laser light, it generates reactive oxygen species that destroy tumor-associated blood vessels.
आणविक भार
916.4000 g/mol
TPSA
240.00 Ų
क्रिया का तंत्र
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.
SMILES
CC[C@@H]1[C@H](C2=CC\3=NC(=C(/C3=C(\C)/[O-])C)C=C4[C@H]([C@@H](C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=NCCS(=O)(=O)[O-])[O-])CC(=O)OC)CCC(=O)[O-])C)C.[K+].[K+].[Pd+2]
InChI
InChI=1S/C37H45N5O9S.2K.Pd/c1-8-22-17(2)25-16-30-33(21(6)43)19(4)27(40-30)14-26-18(3)23(9-10-31(44)45)35(41-26)24(13-32(46)51-7)36-34(37(47)38-11-12-52(48,49)50)20(5)28(42-36)15-29(22)39-25;;;/h14-18,22-23,39,43H,8-13H2,1-7H3,(H,38,47)(H,44,45)(H,48,49,50);;;/q;2*+1;+2/p-4/b25-16?,26-14?,29-15?,33-21-,36-24?;;;/t17-,18+,22-,23+;;;/m1.../s1
Molecular Formula
C37H41K2N5O9PdS
HBD / HBA
1 / 14
घूर्णनीय बंधन
9
भारी परमाणु
55
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
अक्सर पूछे जाने वाले प्रश्न
A potassium salt of padeliporfin (WST11), a photosensitizer used in vascular-targeted photodynamic therapy for localized low-risk prostate cancer. When activated by near-infrared laser light, it generates reactive oxygen species that destroy tumor-associated blood vessels.
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.
Yes, Padeliporfin Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594285. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135391044. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="padeliporfin-potassium"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/padeliporfin-potassium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/padeliporfin-potassium/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/padeliporfin-potassium/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="padeliporfin-potassium"></drugfyi-drug>